Let’s Start this Interesting Article Shared on DesiNew.xyz
NEW DELHI: Dismissing reports of Health hazard From Hydroxychloroquine (HCQ), according to simmering reports cited by the World Health Organization (WHO), Director General of the Council of Scientific and Industrial Research (CSIR) of India, Shekhar Mande, said on Wednesday that studies related to anti-malarial drugs, which led to drug use Is suspended, not a randomized clinical trial and only an analysis of Hospital register Worldwide.
WHO on Sunday announced a temporary suspension of clinical trials of hydroxychloroquine, which are used for treatment COVID-19 patientsA study published in the online medical journal The Lancet found that drug use increased the risk of death by 34 percent and that of heart arrhythmia by 137 percent.
Based on 96,000 hospital registries, researchers concluded that the situation worsened when severe patients, when given hydroxychloroquine, did not show improvement in some.
“The Lancet study is based on hospital registry data. This is not a randomized clinical trial. It is simply an analysis of hospital registers worldwide. But even then, in some people, the situation has worsened, and WHO has Temporarily halted use. Madee told ANI, “I’m sure WHO will consider this in the coming time.”
Indian researchers have not detected any major side effects of HCQ and its use should be continued in preventive treatment for COVID-19, Indian Council of Medical Research (ICMR) said on Tuesday.
The official said, “Therefore, we should trust ICMR’s decision. ICMR people are exceptionally qualified. If they say it should be continued, then we should trust their decision and continue this medicine . ”
He further stated that CSIR does not have any specific suggestion about hydroxychloroquine. “All it can do is to conduct a clinical trial. At this time, hydroxychloroquine is not on our radar to conduct any clinical trials. So CSIR is never advised to recommend any specific drug formulation test Necessarily, we will do so on the basis of scientific evidence. ” , But we have not generated any scientists on hydroxychloroquine on our own.
On the basis of profile access, people should take hydroxychloroquine, with people who are at high risk of exposure to a Kovid patient due to their family ties and profession, said Mande. He said, “I don’t think ICMR ever advises that seriously ill patients and ventilators should all be given hydroxychloroquine. But we should really trust what ICMR has advised.”
During an extraordinary meeting of the WHO’s Solidarity Trial Working Group on Sunday, the Global Health Body suspended the allocation of patients to the hydroxychloroquine arm of the Solidarity Trial. The call will be made after reviewing the existing evidence. Patients who previously had randomization in the HCQ arm would complete their treatment.
India, however, continues to use the drug, along with azithromycin, For prophylaxis among family members of health and other border workers and Kovid positive patients.
Ministry of Health of India It also wrote to the WHO after the decision was made, “It appears all reports about the safety and efficacy of HCQ have not been considered before giving the decision to stop the HCQ clinical trial.”
STAY TUNED WITH US FOR MORE INTERESTING CONTENT ONLY ON DESINEW.XYZ